Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) was the target of a significant growth in short interest during the month of October. As of October 30th, there was short interest totaling 585,071 shares, a growth of 120.4% from the October 15th total of 265,423 shares. Approximately 4.8% of the shares of the company are sold short. Based on an average daily volume of 1,925,065 shares, the short-interest ratio is currently 0.3 days.
Institutional Trading of Fractyl Health
Several hedge funds and other institutional investors have recently bought and sold shares of GUTS. Sanctuary Advisors LLC bought a new stake in shares of Fractyl Health in the 2nd quarter valued at about $26,000. Private Advisor Group LLC acquired a new stake in Fractyl Health in the third quarter worth about $27,000. FNY Investment Advisers LLC grew its position in Fractyl Health by 84.3% during the 2nd quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock worth $51,000 after purchasing an additional 29,920 shares during the last quarter. PEAK6 LLC purchased a new stake in shares of Fractyl Health during the second quarter valued at $159,000. Finally, Mink Brook Asset Management LLC grew its stake in Fractyl Health by 62.5% during the 3rd quarter. Mink Brook Asset Management LLC now owns 573,145 shares of the company’s stock valued at $312,000 after purchasing an additional 220,400 shares during the last quarter.
Analyst Ratings Changes
A number of brokerages have recently issued reports on GUTS. Morgan Stanley cut their price objective on shares of Fractyl Health to $4.00 and set an “equal weight” rating for the company in a research report on Monday, October 19th. Wall Street Zen cut Fractyl Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings cut Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Finally, Craig Hallum set a $5.00 price objective on Fractyl Health in a research note on Monday, October 19th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $50.25.
View Our Latest Analysis on GUTS
Fractyl Health Stock Performance
Shares of GUTS stock opened at $0.90 on Monday. The company has a current ratio of 1.98, a quick ratio of 1.98 and a debt-to-equity ratio of 1.41. Fractyl Health has a 12-month low of $0.80 and a 12-month high of $29.34. The stock’s 50-day moving average price is $3.89 and its 200-day moving average price is $6.87. The stock has a market capitalization of $11.98 million, a price-to-earnings ratio of -0.29 and a beta of 2.91.
Fractyl Health (NASDAQ:GUTS – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($1.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.50) by $0.43. Equities research analysts predict that Fractyl Health will post -5.88 EPS for the current fiscal year.
About Fractyl Health
Fractyl Health is a clinical-stage therapeutics company focused on developing treatments for metabolic diseases, including type 2 diabetes and obesity. The company is based in Burlington, Massachusetts. Its lead program, Revita, is an investigational endoscopic procedure designed to resurface the lining of the duodenum, the first part of the small intestine. Fractyl is studying whether this approach can improve metabolic function and provide lasting benefits for people with type 2 diabetes. The company is also developing Rejuva, an experimental gene therapy platform intended to address obesity and related metabolic conditions.
See Also
- Five stocks we like better than Fractyl Health
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
